{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:23:54Z","timestamp":1763043834299,"version":"3.45.0"},"reference-count":48,"publisher":"Informa UK Limited","issue":"17","funder":[{"name":"Zhaoyang Teng, Cedric Fernandez and Sean Corbet"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.1080\/14796694.2025.2515778","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T03:49:24Z","timestamp":1749527364000},"page":"2225-2235","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia"],"prefix":"10.1080","volume":"21","author":[{"given":"Manuel David","family":"Gil-Sierra","sequence":"first","affiliation":[{"name":"Andalusian Health Service","place":["Sevilla, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Mantopoulos","sequence":"additional","affiliation":[{"name":"IQVIA ltd","place":["Athens, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifigeneia","family":"Barouma","sequence":"additional","affiliation":[{"name":"IQVIA ltd","place":["Athens, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Hauch","sequence":"additional","affiliation":[{"name":"Hauch Consultancy","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyang","family":"Teng","sequence":"additional","affiliation":[{"name":"Servier Pharmaceuticals","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Servier International","place":["Suresnes, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Corbet","sequence":"additional","affiliation":[{"name":"Servier International","place":["Suresnes, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Schlueter","sequence":"additional","affiliation":[{"name":"IQVIA ltd","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"crossref","unstructured":"Estey E D\u00f6hner H. Acute myeloid leukaemia. (1474-547X (electronic). 2006.","DOI":"10.1016\/S0140-6736(06)69780-8"},{"key":"e_1_3_6_4_1","unstructured":"Licht JD Sternberg DW. The molecular pathology of acute myeloid leukemia. (1520\u20134383 (electronic))."},{"key":"e_1_3_6_5_1","unstructured":"SEER cancer stat facts: acute myeloid leukemia (AML). 2018. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"e_1_3_6_6_1","doi-asserted-by":"crossref","unstructured":"Xu Q Li Y Lv N et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. (1557\u20133265 (electronic)). 2017.","DOI":"10.1158\/1078-0432.CCR-16-2628"},{"key":"e_1_3_6_7_1","doi-asserted-by":"crossref","unstructured":"Bullinger L D\u00f6hner K D\u00f6hner H. Genomics of acute myeloid leukemia diagnosis and pathways. (1527\u20137755 (electronic)). J Clin Oncol. 2017 Mar 20;35(9):934\u2013946.","DOI":"10.1200\/JCO.2016.71.2208"},{"key":"e_1_3_6_8_1","unstructured":"SEER. Cancer Stat Facts: Leukemia \u2014 Acute Myeloid Leukemia (AML). 2023 [cited 2023 May 30]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"e_1_3_6_9_1","doi-asserted-by":"crossref","unstructured":"Marcucci G Maharry K Fau - Wu Y-Z et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. (1527\u20137755 (electronic)). J Clin Oncol. 2010 May 10;28(14):2348\u201355.","DOI":"10.1200\/JCO.2009.27.3730"},{"key":"e_1_3_6_10_1","unstructured":"Mardis ER Ding L Fau - Dooling DJ Dooling Dj Fau - Larson DE et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. (1533\u20134406 (electronic)). N Engl J Med. 2009 Sep 10;361(11):1058\u201366."},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001920"},{"key":"e_1_3_6_12_1","volume-title":"Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology","author":"National Comprehensive Cancer Network","year":"2023","unstructured":"National Comprehensive Cancer Network. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023 May;21(5):503\u2013513."},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001779"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"e_1_3_6_17_1","unstructured":"Food and Drug Administration. TIBSOVO\u00ae (ivosidenib tablets) for oral use: highlights of prescribing information. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211192_s008lbl.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1286"},{"key":"e_1_3_6_19_1","article-title":"Cochrane Handbook for systematic reviews of interventions version 6.2 (updated February 2021)","author":"Higgins JP","year":"2021","unstructured":"Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for systematic reviews of interventions version 6.2 (updated February 2021). Cochrane. 2021.","journal-title":"Cochrane"},{"key":"e_1_3_6_20_1","volume-title":"NICE guidelines","author":"National Institute for Health and Care Excellence","year":"2021","unstructured":"National Institute for Health and Care Excellence. NICE guidelines. 2021 [Cited 2023 Jun 18]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36"},{"key":"e_1_3_6_21_1","unstructured":"Dias S Welton NJ Sutton AJ et al. E NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148049"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0280"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_6_25_1","doi-asserted-by":"crossref","unstructured":"Vives S-O Mart\u00ednez-Cuadr\u00f3n D Bergua Burgues J et al. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. (1097\u20130142 (electronic)). Cancer. 2021 Jun 15;127(12):2003\u20132014.","DOI":"10.1002\/cncr.33403"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102458"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02001-z"},{"key":"e_1_3_6_28_1","doi-asserted-by":"crossref","unstructured":"DiNardo CD Jonas BA Pullarkat V et al. Azacitidine and venetoclax in Previously untreated acute myeloid leukemia. (1533\u20134406 (electronic)). N Engl J Med. 2020 Aug 13;383(7):617\u2013629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20130432.CCR\u201321\u20133467"},{"key":"e_1_3_6_30_1","unstructured":"European Medicines Agency. Venclyxto EPAR product information Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf"},{"issue":"3","key":"e_1_3_6_31_1","first-page":"415","article-title":"Low-dose cytarabine versus best supportive care for patients with acute myeloid leukaemia unfit for the standard of care: Egyptian centre experience","volume":"12","author":"Mohammed AE","year":"2021","unstructured":"Mohammed AE. Low-dose cytarabine versus best supportive care for patients with acute myeloid leukaemia unfit for the standard of care: Egyptian centre experience. Middle East J Cancer. 2021;12(3):415\u2013421.","journal-title":"Middle East J Cancer"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24072"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004934"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123012"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27246"},{"key":"e_1_3_6_36_1","doi-asserted-by":"crossref","unstructured":"Heuser M-O Smith BD Fiedler W et al. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. (1432\u20130584 (electronic)). Ann Hematol. 2021 May;100(5):1181\u20131194.","DOI":"10.1007\/s00277-021-04465-4"},{"key":"e_1_3_6_37_1","doi-asserted-by":"crossref","unstructured":"Kantarjian HM Thomas Xg Fau - Dmoszynska A Dmoszynska A et al. Multicenter randomized open-label phase III trial of decitabine versus patient choice with physician advice of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. (1527\u20137755 (electronic)). J Clin Oncol. 2012 Jul 20;30(21):2670-7.","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"e_1_3_6_38_1","doi-asserted-by":"crossref","unstructured":"Dombret H Seymour JF Butrym A et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. (1528\u20130020 (electronic)). Blood. 2015 Jul 16;126(3):291\u20139.","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_6_39_1","doi-asserted-by":"crossref","unstructured":"Wei A-O Panayiotidis P Montesinos P-O et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141\/150). (2044\u20135385 (electronic)). Blood Cancer J. 2021 Oct 1;11(10):163.","DOI":"10.1038\/s41408-021-00565-6"},{"key":"e_1_3_6_40_1","unstructured":"European Medicines Agency. Tibsovo summary of product characteristics online. 2023 [cited 2023 Jul May]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tibsovo-epar-product-information_en.pdf"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025409"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-06823-y"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173033"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2411436"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2023.2247200"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2206489"},{"key":"#cr-split#-e_1_3_6_47_1.1","unstructured":"European Medicines Agency. EMA\/COMP position on review of criteria for orphan designation - tibsovo (ivosidenib) online. 2023 [updated 2023 May 4"},{"key":"#cr-split#-e_1_3_6_47_1.2","unstructured":"cited 2023 May 31]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/tibsovo-orphan-maintenance-assessment-report-initial-authorisation_en.pdf"},{"key":"e_1_3_6_48_1","unstructured":"Excellence NIfHa C. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]. 2024 [cited 2024 May 22]. Available from: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11167\/documents"},{"key":"e_1_3_6_49_1","volume-title":"Ivosidenib (tibsovo): indication: ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy: reimbursement recommendation","author":"CADTH Reimbursement Reviews and Recommendations","year":"2024","unstructured":"CADTH Reimbursement Reviews and Recommendations. Ivosidenib (tibsovo): indication: ivosidenib in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive intensive induction chemotherapy: reimbursement recommendation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2515778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:19:26Z","timestamp":1763043566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2515778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":48,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,7,15]]}},"alternative-id":["10.1080\/14796694.2025.2515778"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2515778","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}